Assessment of Neuroendocrine Tumors' Heterogeneity with Combination of Molecular Imaging Studies Abstract #863

Introduction: Neuroendocrine tumors (NET) are heterogeneous neoplasms. The choice of the appropriate molecular imaging study for assessment of disease extent usually depends on tumor grade.
Aim(s): To assess the value of combination of molecular imaging when a heterogeneous cell population is suspected or established.
Materials and methods: Patients with different-grade NET lesions, confirmed with biopsies and existing simultaneously, were identified. All patients had two molecular imaging studies Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and Gallium-68 octreotate PET (Ga-68 DOTATATE) around the same period.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Roberta E Rossi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#16 Endoglin as indicator of metastatic neuroendocrine tumors of the pancreas
Introduction: Neuroendocrine tumors of the pancreas are rare, highly vascularized tumors. Endoglin, a Transforming Growth Factor-β co-receptor, is a marker for angiogenic endothelial cells. Angiogenesis is required for tumor progression and the development of metastases. Recently, endoglin expression was found to be a prognostic marker in pancreatic carcinomas. However, the role of endoglin in neuroendocrine pancreatic tumors has so far not been studied.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Patricia Kuiper
#26 Molecular imaging of gastroenteropancreatic neuroendocrine tumours with Ga-68 DOTANOC PET/CT and correlation with an immunhistochemical quantification of somatostatin receptors using novel monoclonal and polyclonal antibodies
Introduction: Receptor PET/CT with somatostatin analogues marked with Gallium-68 (SMS-R-PET/CT) is currently the golden standard in diagnosing gastroenteropancreatic neuroendocrine tumors (GEP-NET), which are known for an overexpression of somatostatin receptors (SSTRs).

Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Daniel Kaemmerer
#51 Epidemiology of the neuroendocrine tumors diagnosed in Cardarelli Hospital: a retrospective single-institution analysis of 274 cases
Introduction: Neuroendocrine tumors (NETs) are considered rare tumors and are characterized by their ability to produce peptides that cause typical hormonal syndromes. Neuroendocrine tumors consist of a wide spectrum of malignancies with different histology that can arise from distributed neuroendocrine cells in the body. Although these tumors are frequently indolent, they can be aggressive and resistant to therapy. Its incidence in the U.S.A has been rising in the last three decades (Surveillance, Epidemiology, and End Results registry). NETs are more common than generally believed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ferdinando Riccardi
#59 Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors
Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Georgios Kanakis
#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.